Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Forte Biosciences

Tracked across 3 events · 19 articles · First seen Apr 08, 2026 · Last active Aug 20, 2026

Sentiment
37
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 20
Business
Impact: Forte Biosciences commenced and priced a public offering of its common stock to raise approximately $150 million for working capital and clinical development.
Apr 08, 2026 · 7 articles
4 80
Business
Impact: Forte is being acquired at a significant premium; its lead asset FB102 gains access to Argenx's development and commercial capabilities.
Jul 27, 2026 · 6 articles
1 10
Tech
Forte Biosciences, a clinical-stage biotechnology company, announced it will host an educational symposium at PAINWeek 2026 titled 'A New Era in Pain Therapeutics.' The symposium will showcase the company's neural reset strategy for its botanical…
Impact: Hosting the symposium and presenting its CY200 candidate and safety switch technologies, Ensysce aims to raise awareness and potentially advance its clinical development. The event is a promotional opportunity but does not alter its financial position.
Aug 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Forte Biosciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.